Llwytho...
Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease
Over the past few decades, a series of innovative medicines have been developed in order to optimize anticoagulation therapy for atrial fibrillation (AF). As a result, a number of nonvitamin K antagonist oral anticoagulants (NOAC) that directly target the enzymatic activity of factor II and factor X...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Medicina (Kaunas) |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
MDPI
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8147111/ https://ncbi.nlm.nih.gov/pubmed/33925501 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/medicina57050422 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|